



480-A21

Application No. 09/926,218

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Arne HOLMGREN et al.

Group Art Unit : 1621

Appl. No : 09/926,218

(National Stage of PCT/JP00/02076)

Examiner : Kumar

I.A. Filed : March 31, 2000

For : SUBSTRATE FOR THIOREDOXIN REDUCTASE

### THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
U.S. Patent and Trademark Office  
Customer Service Window, Mail Stop Amendment  
Randolph Building  
401 Dulany Street  
Alexandria, VA 22314

Sir :

Further to the previously filed Information Disclosure Statements, Applicants hereby bring the following information to the attention of the Examiner.

Holmgren A., Thioredoxin, Ann. Rev. Biochem., 54:237-271, 1985

Schewe, T., Gen. Pharmacol. 26, Vol. 26, No. 6, 1153-1169, 1995

A lecture by Arne Holmgren at a conference at the Pasteur Institute disclosing the results that mammalian thioredoxin reductase was a selenoprotein with a selenocysteine residue in the active site, which was later published in Oxidative Stress, in Cancer, AIDS and Neurodegenerative Diseases (Montagnier, Olivier, Pasquier, Eds.) Marcel Dekker, Inc., New York, pp 229-246, 1998, "23 Redox Regulation by the Thioredoxin and Glutaredoxin Systems", Holmgren et al.

12/01/2006 JADD01 00000015 09926218

02 FC:1036

100.00 09

Copies of the above-noted documents are enclosed together with a duly completed Form PTO-1449. The Examiner is accordingly requested to consider each of these

P21480.A21


Application No. 09/926,218

documents, and to make them of record in this application by initialing in the appropriate spaces on the Form-1449. Applicants respectfully request that the Examiner include a copy of the initialed Form PTO-1449 with the next communication from the U.S. Patent and Trademark Office.

Applicants enclose \$180.00 in payment of the fee for consideration of this Information Disclosure Statement. If any fee is needed for consideration of the this paper and the information cited therein, authorization is hereby provided to charge any required fee, including any fee under 37 C.F.R. 1.17(p), to Deposit Account No. 19-0089.

Any comments or questions concerning this application can be directed to the undersigned at the telephone number given below.

Respectfully submitted,  
Arne HOLMGREN et al.

  
\_\_\_\_\_  
Bruce H. Bernstein  
Reg. No. 29,027


November 30, 2006  
GREENBLUM & BERNSTEIN, P.L.C.  
1950 Roland Clarke Place  
Reston, VA 20191  
(703) 716-1191

Arnold Turk  
Reg. No. 33094

Application No.  
09/926,218

(Use several sheets if necessary)

Group  
1621

[illegible][illegible]

	1	Holmgren A., Thioredoxin, Ann. Rev. Biochem., 54:237-271, 1985.
	2	Schewe, T., Gen. Pharmacol. 26, Vol. 26, No. 6, 1153-1169, 1995.
	3	A lecture by Arne Holmgren at a conference at the Pasteur Institute disclosing the results that mammalian thioredoxin reductase was a selenoprotein with a selenocysteine residue in the active site, which was later published in Oxidative Stress, in Cancer, AIDS and Neurodegenerative Diseases (Montagnier, Olivier, Pasquier, Eds.) Marcel Dekker, Inc., New York, pp 229-246, 1998, "23 Redox Regulation by the Thioredoxin and Glutaredoxin Systems", Holmgren et al..

DATE CONSIDERED

{P21480 00095042.DOC}